Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Conformational Plasticity in the HIV-1 Fusion Peptide Facilitates Recognition by Broadly Neutralizing Antibodies.

Yuan M, Cottrell CA, Ozorowski G, van Gils MJ, Kumar S, Wu NC, Sarkar A, Torres JL, de Val N, Copps J, Moore JP, Sanders RW, Ward AB, Wilson IA.

Cell Host Microbe. 2019 Jun 12;25(6):873-883.e5. doi: 10.1016/j.chom.2019.04.011.

2.

The Chimpanzee SIV Envelope Trimer: Structure and Deployment as an HIV Vaccine Template.

Andrabi R, Pallesen J, Allen JD, Song G, Zhang J, de Val N, Gegg G, Porter K, Su CY, Pauthner M, Newman A, Bouton-Verville H, Garces F, Wilson IA, Crispin M, Hahn BH, Haynes BF, Verkoczy L, Ward AB, Burton DR.

Cell Rep. 2019 May 21;27(8):2426-2441.e6. doi: 10.1016/j.celrep.2019.04.082.

3.

Development of Neutralizing Antibodies against Zika Virus Based on Its Envelope Protein Structure.

Yang C, Gong R, de Val N.

Virol Sin. 2019 Apr;34(2):168-174. doi: 10.1007/s12250-019-00093-5. Epub 2019 Apr 24. Review.

4.

Structures and operating principles of the replisome.

Gao Y, Cui Y, Fox T, Lin S, Wang H, de Val N, Zhou ZH, Yang W.

Science. 2019 Feb 22;363(6429). pii: eaav7003. doi: 10.1126/science.aav7003. Epub 2019 Jan 24.

5.

Rational Design of DNA-Expressed Stabilized Native-Like HIV-1 Envelope Trimers.

Aldon Y, McKay PF, Allen J, Ozorowski G, Felfödiné Lévai R, Tolazzi M, Rogers P, He L, de Val N, Fábián K, Scarlatti G, Zhu J, Ward AB, Crispin M, Shattock RJ.

Cell Rep. 2018 Sep 18;24(12):3324-3338.e5. doi: 10.1016/j.celrep.2018.08.051.

6.

Structure-Guided Redesign Improves NFL HIV Env Trimer Integrity and Identifies an Inter-Protomer Disulfide Permitting Post-Expression Cleavage.

Yang L, Sharma SK, Cottrell C, Guenaga J, Tran K, Wilson R, Behrens AJ, Crispin M, de Val N, Wyatt RT.

Front Immunol. 2018 Jul 17;9:1631. doi: 10.3389/fimmu.2018.01631. eCollection 2018.

7.

Cleavage-Independent HIV-1 Trimers From CHO Cell Lines Elicit Robust Autologous Tier 2 Neutralizing Antibodies.

Bale S, Martiné A, Wilson R, Behrens AJ, Le Fourn V, de Val N, Sharma SK, Tran K, Torres JL, Girod PA, Ward AB, Crispin M, Wyatt RT.

Front Immunol. 2018 May 24;9:1116. doi: 10.3389/fimmu.2018.01116. eCollection 2018.

8.

Structure of a cleavage-independent HIV Env recapitulates the glycoprotein architecture of the native cleaved trimer.

Sarkar A, Bale S, Behrens AJ, Kumar S, Sharma SK, de Val N, Pallesen J, Irimia A, Diwanji DC, Stanfield RL, Ward AB, Crispin M, Wyatt RT, Wilson IA.

Nat Commun. 2018 May 16;9(1):1956. doi: 10.1038/s41467-018-04272-y.

9.

Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins.

Schiffner T, Pallesen J, Russell RA, Dodd J, de Val N, LaBranche CC, Montefiori D, Tomaras GD, Shen X, Harris SL, Moghaddam AE, Kalyuzhniy O, Sanders RW, McCoy LE, Moore JP, Ward AB, Sattentau QJ.

PLoS Pathog. 2018 May 10;14(5):e1006986. doi: 10.1371/journal.ppat.1006986. eCollection 2018 May.

10.

Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model.

Voss JE, Andrabi R, McCoy LE, de Val N, Fuller RP, Messmer T, Su CY, Sok D, Khan SN, Garces F, Pritchard LK, Wyatt RT, Ward AB, Crispin M, Wilson IA, Burton DR.

Cell Rep. 2018 Jan 23;22(4):1103. doi: 10.1016/j.celrep.2017.10.089. Epub 2018 Jan 28. No abstract available.

11.

HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage.

Landais E, Murrell B, Briney B, Murrell S, Rantalainen K, Berndsen ZT, Ramos A, Wickramasinghe L, Smith ML, Eren K, de Val N, Wu M, Cappelletti A, Umotoy J, Lie Y, Wrin T, Algate P, Chan-Hui PY, Karita E; IAVI Protocol C Investigators; IAVI African HIV Research Network, Ward AB, Wilson IA, Burton DR, Smith D, Pond SLK, Poignard P.

Immunity. 2017 Nov 21;47(5):990-1003.e9. doi: 10.1016/j.immuni.2017.11.002.

12.

Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding.

Kulp DW, Steichen JM, Pauthner M, Hu X, Schiffner T, Liguori A, Cottrell CA, Havenar-Daughton C, Ozorowski G, Georgeson E, Kalyuzhniy O, Willis JR, Kubitz M, Adachi Y, Reiss SM, Shin M, de Val N, Ward AB, Crotty S, Burton DR, Schief WR.

Nat Commun. 2017 Nov 21;8(1):1655. doi: 10.1038/s41467-017-01549-6.

13.

Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model.

Voss JE, Andrabi R, McCoy LE, de Val N, Fuller RP, Messmer T, Su CY, Sok D, Khan SN, Garces F, Pritchard LK, Wyatt RT, Ward AB, Crispin M, Wilson IA, Burton DR.

Cell Rep. 2017 Oct 3;21(1):222-235. doi: 10.1016/j.celrep.2017.09.024. Erratum in: Cell Rep. 2018 Jan 23;22(4):1103.

14.

Targeted N-glycan deletion at the receptor-binding site retains HIV Env NFL trimer integrity and accelerates the elicited antibody response.

Dubrovskaya V, Guenaga J, de Val N, Wilson R, Feng Y, Movsesyan A, Karlsson Hedestam GB, Ward AB, Wyatt RT.

PLoS Pathog. 2017 Sep 13;13(9):e1006614. doi: 10.1371/journal.ppat.1006614. eCollection 2017 Sep.

15.

Hidden Lineage Complexity of Glycan-Dependent HIV-1 Broadly Neutralizing Antibodies Uncovered by Digital Panning and Native-Like gp140 Trimer.

He L, Lin X, de Val N, Saye-Francisco KL, Mann CJ, Augst R, Morris CD, Azadnia P, Zhou B, Sok D, Ozorowski G, Ward AB, Burton DR, Zhu J.

Front Immunol. 2017 Aug 24;8:1025. doi: 10.3389/fimmu.2017.01025. eCollection 2017.

16.

Open and closed structures reveal allostery and pliability in the HIV-1 envelope spike.

Ozorowski G, Pallesen J, de Val N, Lyumkis D, Cottrell CA, Torres JL, Copps J, Stanfield RL, Cupo A, Pugach P, Moore JP, Wilson IA, Ward AB.

Nature. 2017 Jul 20;547(7663):360-363. doi: 10.1038/nature23010. Epub 2017 Jul 12.

17.

Glycine Substitution at Helix-to-Coil Transitions Facilitates the Structural Determination of a Stabilized Subtype C HIV Envelope Glycoprotein.

Guenaga J, Garces F, de Val N, Stanfield RL, Dubrovskaya V, Higgins B, Carrette B, Ward AB, Wilson IA, Wyatt RT.

Immunity. 2017 May 16;46(5):792-803.e3. doi: 10.1016/j.immuni.2017.04.014.

18.

Differential Antibody Responses to Conserved HIV-1 Neutralizing Epitopes in the Context of Multivalent Scaffolds and Native-Like gp140 Trimers.

Morris CD, Azadnia P, de Val N, Vora N, Honda A, Giang E, Saye-Francisco K, Cheng Y, Lin X, Mann CJ, Tang J, Sok D, Burton DR, Law M, Ward AB, He L, Zhu J.

MBio. 2017 Feb 28;8(1). pii: e00036-17. doi: 10.1128/mBio.00036-17.

19.

An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability.

van Gils MJ, van den Kerkhof TL, Ozorowski G, Cottrell CA, Sok D, Pauthner M, Pallesen J, de Val N, Yasmeen A, de Taeye SW, Schorcht A, Gumbs S, Johanna I, Saye-Francisco K, Liang CH, Landais E, Nie X, Pritchard LK, Crispin M, Kelsoe G, Wilson IA, Schuitemaker H, Klasse PJ, Moore JP, Burton DR, Ward AB, Sanders RW.

Nat Microbiol. 2016 Nov 14;2:16199. doi: 10.1038/nmicrobiol.2016.199.

20.

Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies.

Briney B, Sok D, Jardine JG, Kulp DW, Skog P, Menis S, Jacak R, Kalyuzhniy O, de Val N, Sesterhenn F, Le KM, Ramos A, Jones M, Saye-Francisco KL, Blane TR, Spencer S, Georgeson E, Hu X, Ozorowski G, Adachi Y, Kubitz M, Sarkar A, Wilson IA, Ward AB, Nemazee D, Burton DR, Schief WR.

Cell. 2016 Sep 8;166(6):1459-1470.e11. doi: 10.1016/j.cell.2016.08.005.

21.

Structures of Ebola virus GP and sGP in complex with therapeutic antibodies.

Pallesen J, Murin CD, de Val N, Cottrell CA, Hastie KM, Turner HL, Fusco ML, Flyak AI, Zeitlin L, Crowe JE Jr, Andersen KG, Saphire EO, Ward AB.

Nat Microbiol. 2016 Aug 8;1(9):16128. doi: 10.1038/nmicrobiol.2016.128.

22.

Thermostability of Well-Ordered HIV Spikes Correlates with the Elicitation of Autologous Tier 2 Neutralizing Antibodies.

Feng Y, Tran K, Bale S, Kumar S, Guenaga J, Wilson R, de Val N, Arendt H, DeStefano J, Ward AB, Wyatt RT.

PLoS Pathog. 2016 Aug 3;12(8):e1005767. doi: 10.1371/journal.ppat.1005767. eCollection 2016 Aug.

23.

Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles.

He L, de Val N, Morris CD, Vora N, Thinnes TC, Kong L, Azadnia P, Sok D, Zhou B, Burton DR, Wilson IA, Nemazee D, Ward AB, Zhu J.

Nat Commun. 2016 Jun 28;7:12041. doi: 10.1038/ncomms12041.

24.

Uncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastability.

Kong L, He L, de Val N, Vora N, Morris CD, Azadnia P, Sok D, Zhou B, Burton DR, Ward AB, Wilson IA, Zhu J.

Nat Commun. 2016 Jun 28;7:12040. doi: 10.1038/ncomms12040.

25.

Structure-Guided Redesign Increases the Propensity of HIV Env To Generate Highly Stable Soluble Trimers.

Guenaga J, Dubrovskaya V, de Val N, Sharma SK, Carrette B, Ward AB, Wyatt RT.

J Virol. 2015 Dec 30;90(6):2806-17. doi: 10.1128/JVI.02652-15.

26.

Affinity Maturation of a Potent Family of HIV Antibodies Is Primarily Focused on Accommodating or Avoiding Glycans.

Garces F, Lee JH, de Val N, de la Pena AT, Kong L, Puchades C, Hua Y, Stanfield RL, Burton DR, Moore JP, Sanders RW, Ward AB, Wilson IA.

Immunity. 2015 Dec 15;43(6):1053-63. doi: 10.1016/j.immuni.2015.11.007.

27.

Chemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer Antigens.

Schiffner T, de Val N, Russell RA, de Taeye SW, de la Peña AT, Ozorowski G, Kim HJ, Nieusma T, Brod F, Cupo A, Sanders RW, Moore JP, Ward AB, Sattentau QJ.

J Virol. 2015 Oct 28;90(2):813-28. doi: 10.1128/JVI.01942-15. Print 2016 Jan 15.

28.

Model Building and Refinement of a Natively Glycosylated HIV-1 Env Protein by High-Resolution Cryoelectron Microscopy.

Lee JH, de Val N, Lyumkis D, Ward AB.

Structure. 2015 Oct 6;23(10):1943-1951. doi: 10.1016/j.str.2015.07.020. Epub 2015 Sep 17.

29.

Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design.

Sharma SK, de Val N, Bale S, Guenaga J, Tran K, Feng Y, Dubrovskaya V, Ward AB, Wyatt RT.

Cell Rep. 2015 Apr 28;11(4):539-50. doi: 10.1016/j.celrep.2015.03.047. Epub 2015 Apr 16.

30.

A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene.

Pugach P, Ozorowski G, Cupo A, Ringe R, Yasmeen A, de Val N, Derking R, Kim HJ, Korzun J, Golabek M, de Los Reyes K, Ketas TJ, Julien JP, Burton DR, Wilson IA, Sanders RW, Klasse PJ, Ward AB, Moore JP.

J Virol. 2015 Mar;89(6):3380-95. doi: 10.1128/JVI.03473-14. Epub 2015 Jan 14.

31.

Well-ordered trimeric HIV-1 subtype B and C soluble spike mimetics generated by negative selection display native-like properties.

Guenaga J, de Val N, Tran K, Feng Y, Satchwell K, Ward AB, Wyatt RT.

PLoS Pathog. 2015 Jan 8;11(1):e1004570. doi: 10.1371/journal.ppat.1004570. eCollection 2015 Jan.

32.

Murine anti-vaccinia virus D8 antibodies target different epitopes and differ in their ability to block D8 binding to CS-E.

Matho MH, de Val N, Miller GM, Brown J, Schlossman A, Meng X, Crotty S, Peters B, Xiang Y, Hsieh-Wilson LC, Ward AB, Zajonc DM.

PLoS Pathog. 2014 Dec 4;10(12):e1004495. doi: 10.1371/journal.ppat.1004495. eCollection 2014 Dec.

33.

Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign.

Tran K, Poulsen C, Guenaga J, de Val N, Wilson R, Sundling C, Li Y, Stanfield RL, Wilson IA, Ward AB, Karlsson Hedestam GB, Wyatt RT.

Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):E738-47. doi: 10.1073/pnas.1319512111. Epub 2014 Feb 3. Erratum in: Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):E1159. Proc Natl Acad Sci U S A. 2014 Feb 18;111(7). doi:10.1073/pnas.1403776111. de Val Alda, Natalia [corrected to de Val, Natalia].

34.

Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer.

Lyumkis D, Julien JP, de Val N, Cupo A, Potter CS, Klasse PJ, Burton DR, Sanders RW, Moore JP, Carragher B, Wilson IA, Ward AB.

Science. 2013 Dec 20;342(6165):1484-90. doi: 10.1126/science.1245627. Epub 2013 Oct 31.

35.

A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies.

Sanders RW, Derking R, Cupo A, Julien JP, Yasmeen A, de Val N, Kim HJ, Blattner C, de la Peña AT, Korzun J, Golabek M, de Los Reyes K, Ketas TJ, van Gils MJ, King CR, Wilson IA, Ward AB, Klasse PJ, Moore JP.

PLoS Pathog. 2013 Sep;9(9):e1003618. doi: 10.1371/journal.ppat.1003618. Epub 2013 Sep 19.

36.

Native cysteine residues are dispensable for the structure and function of all five yeast mitotic septins.

de Val N, McMurray MA, Lam LH, Hsiung CC, Bertin A, Nogales E, Thorner J.

Proteins. 2013 Nov;81(11):1964-79. doi: 10.1002/prot.24345. Epub 2013 Aug 19.

37.

Structural analysis of haemin demetallation by L-chain apoferritins.

de Val N, Declercq JP, Lim CK, Crichton RR.

J Inorg Biochem. 2012 Jul;112:77-84. doi: 10.1016/j.jinorgbio.2012.02.031. Epub 2012 Mar 9.

PMID:
22561545
38.

Mass spectrometry studies of demetallation of haemin by recombinant horse L chain apoferritin and its mutant (E 53,56,57,60 Q).

de Val N, Herschbach H, Potier N, Dorsselaer AV, Crichton RR.

FEBS Lett. 2006 Nov 13;580(26):6275-80. Epub 2006 Oct 24.

39.

EPR studies of recombinant horse L-chain apoferritin and its mutant (E 53,56,57,60 Q) with haemin.

de Val N, Hagen WR, Crichton RR.

Biometals. 2007 Feb;20(1):21-6. Epub 2006 May 12.

PMID:
16988881
40.

Optical and EPR spectroscopic studies of demetallation of hemin by L-chain apoferritins.

Carette N, Hagen W, Bertrand L, de Val N, Vertommen D, Roland F, Hue L, Crichton RR.

J Inorg Biochem. 2006 Aug;100(8):1426-35. Epub 2006 Jun 16.

PMID:
16781777

Supplemental Content

Loading ...
Support Center